SCOTTSDALE, Ariz., Oct. 08, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical” or “the Company”) (Nasdaq: DERM), a commercial-stage pharmaceutical company primarily focused on selling and marketing U.S. Food and Drug Administration (“FDA”)-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced that members of Journey Medical’s management team will participate in two October 2025 investor conferences. Details of the events are as fol ...

Summers Value Partners, an investment management company, released its second-quarter 2025 investor letter. A copy of the letter can be downloaded here. The Summers Value Fund LP returned a net return of -1.8% net in Q2 2025, trailing the 8.5% return of the Russell 2000 Index ETF (IWM) and the 4.9% return for the Russell 2000 Value Index ETF (IWN). Year-to-date, the fund is down 12.8% net compared to (-1.8%) and (-3.2%) returns for the indexes, respectively. In addition, you can check the fund’s top 5 hold ...

SCOTTSDALE, Ariz., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical” or “the Company”) (Nasdaq: DERM), a commercial-stage pharmaceutical company primarily focused on selling and marketing U.S. Food and Drug Administration (“FDA”)-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced that Claude Maraoui, Co-Founder, President and Chief Executive Officer, will participate in two September 2025 investor conferences. Details ...

Summary of Journey Medical Corp (DERM) Conference Call - August 20, 2025 Company Overview - **Company Name**: Journey Medical Corporation - **Ticker Symbol**: DERM - **Industry**: Pharmaceutical, specifically focused on dermatology - **Founded**: Approximately 10 years ago, went public in November 2021 - **Average Daily Volume**: About 150,000 shares - **Outstanding Shares**: Approximately 23 million shares [6][5] Key Products and Market Focus - **Market Size**: The dermatology market is valued at nearly $6 billion [7] - **Primary Disease States**: Rosacea, hyperhidrosis, and acne [7] - **Key Product**: Imrozi, launched in April 2025, is the first product developed by Journey Medical and approved by the FDA in November 2024 [8][7] - **Core Business Revenue**: Approximately $55 million in net revenue for 2024 without Imrozi [8] Product Details - **Imrozi**: - Indicated for the treatment of inflammatory lesions, papules, and pustules of rosacea in adults - Lowest strength of minocycline available at 40 mg, with a once-daily dosage [15][16] - Demonstrated superior efficacy compared to Oratia, the only other oral treatment for rosacea [17][19] - Safety profile similar to placebo, with minimal adverse events [27][28] Clinical Trial Results - **Efficacy**: - Over 60% greater IgA success compared to Oratia and over 120% compared to placebo [20] - Approximately 30% greater inflammatory lesion reduction compared to Oratia and over 65% compared to placebo [21] - Fast-acting results observed as early as two weeks [24] Market Access and Growth Strategy - **Market Access**: - Approximately 100 million lives have access to Imrozi, with expectations for growth as payer acceptance increases [35][54] - **Prescription Growth**: - Rapid increase in prescriptions from 1,200 in April to over 5,200 in July 2025 [32] - Unique prescribers increased from 600 to over 1,800 [34][48] - **Sales Territories**: 35 sales territories covering 80 of the top 50 MSAs in the U.S., accessing about 70% of dermatology prescriptions [11][12] Financial Outlook - **Current Run Rate**: Approximately $60 million annually, nearing breakeven [49] - **EBITDA Positive**: Expected to achieve EBITDA positivity later in 2025 due to contributions from Imrozi [38][48] - **Out-Licensing Strategy**: Successful past deals, including a $20 million non-dilutive capital deal for QBREXZA [41][52] Long-Term Strategy - **Focus Areas**: - Continued growth of Imrozi, QBREXZA, and Accutane - Out-licensing opportunities to generate additional capital - Building a strong presence in dermatology with a robust product portfolio [57][40] Conclusion - Journey Medical is positioned for significant growth in the dermatology market with the launch of Imrozi and a strong sales strategy. The company aims to leverage its existing products and expand its market presence while focusing on achieving profitability and sustainable growth in the coming years [42][57].

SCOTTSDALE, Ariz., Aug. 18, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical,” “the Company,” “we” or “our”), a commercial-stage pharmaceutical company primarily focused on selling and marketing FDA-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced that Claude Maraoui, Co-Founder, President and Chief Executive Officer, will present a corporate overview at the Emerging Growth Conference on Wednesday, August 20, 2 ...

Group 1: CoreWeave Inc Financial Results - CoreWeave reported a revenue of $1.21 billion for the second quarter, exceeding analysts' expectations of $1.08 billion [1] - The company's adjusted loss per share was 27 cents, which was worse than the anticipated loss of 17 cents per share [1] Group 2: Stock Movements - CoreWeave shares fell 8.8% to $135.72 in pre-market trading following the mixed quarterly results [2] - Profrac Holding Corp shares tumbled 29.4% to $4.46 after pricing a $75 million stock offering at $4 per share [4] - CAVA Group Inc shares dipped 24% to $64.26 after reporting worse-than-expected quarterly sales results [4] - Journey Medical Corp shares declined 20.5% to $6.79 after reporting disappointing second-quarter EPS results [4] - Ondas Holdings Inc shares fell 17.5% to $3.54 after announcing a proposed public offering [4] - KinderCare Learning Companies Inc shares dropped 16.4% to $8.20 after missing second-quarter earnings estimates and narrowing 2025 guidance [4] - Endeavour Silver Corp shares fell 13.9% to $4.95 after posting a loss for the second quarter [4] - Stratasys Ltd shares dipped 13.4% to $9.80 following second-quarter results [4] - Denison Mines Corp shares declined 8.8% to $1.97 as the company announced the pricing of upsized $300 million convertible senior notes offering [4] - Hanesbrands Inc shares fell 7.7% to $5.70 after a previous jump of 28% due to acquisition news [4] - Penguin Solutions Inc shares fell 5.8% to $22.84 in pre-market trading [4]

Financial Data and Key Metrics Changes - The total net revenue for Q2 2025 was $15 million, compared to $14.9 million for Q2 2024, with $2.8 million attributed to the U.S. commercial launch of Amrozi [15][18] - Gross margin increased to 67% in Q2 2025 from 61% in the prior year [15] - Net loss for common shareholders was $3.8 million or $0.16 per share in Q2 2025, compared to a net loss of $3.4 million or $0.17 per share in Q2 2024 [18] Business Line Data and Key Metrics Changes - Amrozi sales contributed approximately $2.8 million to the total net product revenue, marking a significant improvement in gross profit margins [6][15] - Accutane sales declined by $2.3 million due to generic competition, but growth brands like Amrozi and QBREXZA offset this decline [7][15] - QBREXZA revenue for the quarter was reported at $6.9 million [38] Market Data and Key Metrics Changes - Amrozi achieved over 12,800 prescriptions by July, with a consistent increase in weekly prescriptions since its launch [9][11] - The product captured more than 10% of new prescription demand among dermatology writers within three months of promotion [10] - Payer access for Amrozi increased from 30% of commercial lives in May to approximately 65% by July [10] Company Strategy and Development Direction - The company aims to become sustainably EBITDA positive later in 2025 through strategic initiatives focused on optimizing operations and controlling expenses [6] - The focus remains on expanding the base of Amrozi prescribers, growing prescription volume, and increasing payer access [21] - The company is committed to leveraging its established dermatology commercial organization to enhance product sales and profitability [11][21] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the ongoing momentum of Amrozi's launch and its potential to become the standard of care for rosacea treatment [21] - The company is optimistic about achieving its core objectives, which include improving patient lives and creating long-term shareholder value [22] - Management noted that while there is some seasonality in the dermatology market, the current growth trajectory of Amrozi is expected to continue [35] Other Important Information - Journey Medical's common stock was added to the small-cap Russell 2000 and broad market Russell 3000 indexes, enhancing public awareness and institutional investor ownership [13] - The product was featured in a segment on Lifetime TV, increasing visibility [12] Q&A Session Summary Question: What is the goal for coverage by the end of the year? - Management indicated that while they have not publicly disclosed a specific target, they are focused on increasing both the quantity and quality of coverage for Amrozi [24][25] Question: How do you see gross margins evolving over the year? - Management expects incremental improvements in gross margins as Amrozi becomes a larger part of the sales mix, given its low cost [27][28] Question: When will guidance for the year be provided? - Management stated that it is too early in the launch to provide hard guidance and will wait a few more quarters [29] Question: What is the expected net revenue per prescription for Amrozi? - Management refrained from providing specific guidance on average selling price due to the complexities involved in early quarters [33][34] Question: How does seasonality affect the rosacea market? - Management acknowledged some seasonality but believes the current growth pace will not be significantly impacted [35] Question: What is the market share goal for Amrozi? - Management noted that the 10% market share among high-volume dermatologists is a strong start, with expectations for continued growth [48][50]

[PART I. FINANCIAL INFORMATION](index=3&type=section&id=PART%20I.%20FINANCIAL%20INFORMATION) This part presents the company's unaudited condensed consolidated financial statements and management's discussion and analysis [Item 1. Condensed Consolidated Financial Statements (unaudited)](index=3&type=section&id=Item%201.%20Condensed%20Consolidated%20Financial%20Statements%20%28unaudited%29) Unaudited consolidated financial statements and notes are presented, showing a net loss of $7.9 million for H1 2025 [Unaudited Condensed Consolidated Balance Sheets](index=3&type=section&id=Unaudited%20Condensed%20Consolidated%20Balance%20Sheets) This section presents the company's financial position, detailing assets, liabilities, and equity at specific reporting dates Condensed Consolidated Balance Sheet Highlights (in thousands) | Metric | June 30, 2025 | December 31, 2024 | Change ($) | Change (%) | | :----------------------------- | :------------ | :---------------- | :--------- | :--------- | | Cash and cash equivalents | $20,293 | $20,305 | $(12) | -0.06% | | Total current assets | $51,268 | $48,179 | $3,089 | 6.41% | | Total assets | $81,158 | $80,241 | $917 | 1.14% | | Total current liabilities | $40,481 | $35,175 | $5,306 | 15.09% | | Total liabilities | $61,912 | $60,172 | $1,740 | 2.89% | | Total stockholders' equity | $19,246 | $20,069 | $(823) | -4.10% | [Unaudited Condensed Consolidated Statements of Operations](index=4&type=section&id=Unaudited%20Condensed%20Consolidated%20Statements%20of%20Operations) This section outlines the company's financial performance, including revenues, expenses, and net loss over specific periods Condensed Consolidated Statements of Operations Highlights (in thousands, except per share data) | Metric | 3 Months Ended June 30, 2025 | 3 Months Ended June 30, 2024 | Change ($) | Change (%) | 6 Months Ended June 30, 2025 | 6 Months Ended June 30, 2024 | Change ($) | Change (%) | | :-------------------------------------------------- | :----------------------------- | :----------------------------- | :--------- | :--------- | :----------------------------- | :----------------------------- | :--------- | :--------- | | Product revenue, net | $15,009 | $14,855 | $154 | 1.04% | $28,148 | $27,885 | $263 | 0.94% | | Total operating expenses | $17,885 | $17,782 | $103 | 0.58% | $34,348 | $40,902 | $(6,554) | -16.02% | | Loss from operations | $(2,876) | $(2,927) | $51 | -1.74% | $(6,200) | $(13,017) | $6,817 | -52.37% | | Net loss | $(3,796) | $(3,361) | $(435) | 12.94% | $(7,869) | $(13,803) | $5,934 | -43.00% | | Basic and diluted net loss per common share | $(0.16) | $(0.17) | $0.01 | -5.88% | $(0.34) | $(0.69) | $0.35 | -50.72% | [Unaudited Condensed Consolidated Statements of Changes in Stockholders' Equity](index=5&type=section&id=Unaudited%20Condensed%20Consolidated%20Statements%20of%20Changes%20in%20Stockholders%27%20Equity) This section details changes in the company's equity, reflecting transactions affecting capital and accumulated earnings/losses Condensed Consolidated Statements of Changes in Stockholders' Equity Highlights (in thousands) | Metric | June 30, 2025 | December 31, 2024 | Change ($) | Change (%) | | :-------------------- | :------------ | :---------------- | :--------- | :--------- | | Total Shareholders' Equity | $19,246 | $20,069 | $(823) | -4.10% | | Additional Paid-in Capital | $114,140 | $107,094 | $7,046 | 6.58% | | Accumulated Deficit | $(94,896) | $(87,027) | $(7,869) | 9.04% | - Share-based compensation for the six months ended June 30, 2025, was **$2.659 million**[14](index=14&type=chunk) - Issuance of common stock from ATM offering, net of costs, generated **$4.048 million** for the six months ended June 30, 2025[14](index=14&type=chunk) [Unaudited Condensed Consolidated Statements of Cash Flows](index=6&type=section&id=Unaudited%20Condensed%20Consolidated%20Statements%20of%20Cash%20Flows) This section reports the company's cash inflows and outflows from operating, investing, and financing activities Condensed Consolidated Statements of Cash Flows Highlights (in thousands) | Metric | 6 Months Ended June 30, 2025 | 6 Months Ended June 30, 2024 | Change ($) | Change (%) | | :-------------------------------- | :----------------------------- | :----------------------------- | :--------- | :--------- | | Net cash used in operating activities | $(3,774) | $(10,195) | $6,421 | -62.98% | | Net cash provided by financing activities | $3,762 | $6,668 | $(2,906) | -43.58% | | Net change in cash | $(12) | $(3,527) | $3,515 | -99.66% | | Cash at the end of the period | $20,293 | $23,912 | $(3,619) | -15.13% | - Cash paid for interest increased from **$756k** in 2024 to **$1,591k** in 2025 for the six-month period[22](index=22&type=chunk) [NOTE 1. ORGANIZATION AND PLAN OF BUSINESS OPERATIONS](index=7&type=section&id=NOTE%201.%20ORGANIZATION%20AND%20PLAN%20OF%20BUSINESS%20OPERATIONS) This note describes the company's business, operational structure, and financial viability considerations - Journey Medical Corporation is a commercial-stage pharmaceutical company focused on FDA-approved prescription dermatological products in the U.S., with a portfolio of eight drugs[23](index=23&type=chunk) - The Company is a majority-owned subsidiary of Fortress Biotech, Inc[24](index=24&type=chunk) - Cash and cash equivalents were **$20.3 million** at June 30, 2025, consistent with December 31, 2024. Working capital decreased from **$13.0 million** to **$10.8 million**[25](index=25&type=chunk) - Substantial doubt exists about the Company's ability to continue as a going concern due to recurring losses[28](index=28&type=chunk) [NOTE 2. BASIS OF PRESENTATION](index=7&type=section&id=NOTE%202.%20BASIS%20OF%20PRESENTATION) This note explains the accounting principles, consolidation policies, and significant estimates used in preparing the financial statements - The Company's consolidated financial statements include the accounts of Journey Medical Corporation and its wholly-owned subsidiary, JG Pharma, Inc[29](index=29&type=chunk) - Amortization of acquired intangible assets was reclassified from 'Cost of goods sold' to a separate line item in the consolidated statement of operations, with no impact on previously reported financial results[30](index=30&type=chunk) - The Company is an emerging growth company and has elected the extended transition period for complying with new or revised accounting standards[31](index=31&type=chunk) - Significant estimates include provisions for coupons, chargebacks, rebates, product returns, inventory realization, valuation of intangible assets, useful lives of amortizable intangible assets, and share-based compensation[32](index=32&type=chunk) [NOTE 3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES](index=9&type=section&id=NOTE%203.%20SUMMARY%20OF%20SIGNIFICANT%20ACCOUNTING%20POLICIES) This note references the company's detailed accounting policies and ongoing evaluations of new accounting standards - Significant accounting policies are described in Note 2 of the Company's 2024 Form 10-K[35](index=35&type=chunk) - The Company is evaluating ASU No. 2023-09 (Income Taxes) and ASU No. 2024-03 (Income Statement Expenses) for their potential impact on disclosures[36](index=36&type=chunk)[37](index=37&type=chunk) [NOTE 4. INVENTORY](index=11&type=section&id=NOTE%204.%20INVENTORY) This note provides a breakdown of the company's inventory, including finished goods, work-in-process, raw materials, and reserves Inventory Composition (in thousands) | Inventory Category | June 30, 2025 | December 31, 2024 | Change ($) | Change (%) | | :----------------- | :------------ | :---------------- | :--------- | :--------- | | Finished goods | $9,526 | $11,381 | $(1,855) | -16.30% | | Work-in-process | $369 | $367 | $2 | 0.54% | | Raw materials | $3,66

Second Quarter 2025 Performance Overview [Financial Performance Summary](index=1&type=section&id=Financial%20Performance%20Summary) Q2 2025 net product revenues rose to $15.0 million, gross margin improved to 67%, but increased SG&A led to a $3.8 million net loss | Financial Metric (Q2) | 2025 (Millions) | 2024 (Millions) | Change (YoY) | | :-------------------- | :-------------- | :-------------- | :----------- | | Total Net Product Revenues | $15.0 | $14.9 | +0.7% | | Gross Margin | 67% | 61% | +6 ppts | | SG&A Expenses | $11.9 | $10.3 | +$1.6 | | Net Loss | $(3.8) | $(3.4) | $(0.4) | | Net Loss Per Share (Basic & Diluted) | $(0.16) | $(0.17) | +$0.01 | [CEO Commentary and Strategic Outlook](index=1&type=section&id=CEO%20Commentary%20and%20Strategic%20Outlook) CEO highlighted Emrosi's strong Q2 2025 prescription ramp and expanding payer coverage, positioning for continued growth and operating leverage - Emrosi™ generated **$2.8 million** in net sales in its first full quarter on the market, demonstrating a strong initial prescription ramp and expanding payer coverage[1](index=1&type=chunk)[2](index=2&type=chunk) - The company believes it is well-positioned for continued growth and operating leverage in the second half of 2025 and beyond, driven by Emrosi's launch traction, improved cash generation, and a focused dermatology commercial organization[2](index=2&type=chunk) [Recent Corporate Highlights](index=2&type=section&id=Recent%20Corporate%20Highlights) Journey Medical expanded Emrosi's payer access, presented positive clinical data, joined Russell Indexes, and appointed a new COO - Expanded payer access for Emrosi™ in July 2025, covering over **100 million commercial lives** in the U.S., up from **54 million** in May 2025[9](index=9&type=chunk) - A data analysis from two Phase 3 clinical trials for Emrosi™ was presented in June 2025, confirming that body weight did not affect its efficacy for moderate-to-severe papulopustular rosacea[9](index=9&type=chunk) - Journey Medical joined the Russell 2000® and Russell 3000® Indexes in June 2025[1](index=1&type=chunk)[9](index=9&type=chunk) - Ramsey Alloush was appointed as Chief Operating Officer in April 2025[9](index=9&type=chunk) Condensed Consolidated Financial Statements [Unaudited Condensed Consolidated Balance Sheets](index=4&type=section&id=Unaudited%20Condensed%20Consolidated%20Balance%20Sheets) Total assets increased to $81.16 million by June 30, 2025, driven by accounts receivable, while liabilities rose and equity decreased to $19.25 million | Balance Sheet Item (Thousands) | June 30, 2025 (Thousands) | December 31, 2024 (Thousands) | Change (Thousands) | | :----------------------------- | :------------ | :---------------- | :----- | | Cash and cash equivalents | $20,293 | $20,305 | $(12) | | Accounts receivable, net | $15,644 | $10,231 | +$5,413| | Total current assets | $51,268 | $48,179 | +$3,089| | Total assets | $81,158 | $80,241 | +$917 | | Total current liabilities | $40,481 | $35,175 | +$5,306| | Total liabilities | $61,912 | $60,172 | +$1,740| | Total stockholders' equity | $19,246 | $20,069 | $(823) | [Unaudited Condensed Consolidated Statements of Operations](index=5&type=section&id=Unaudited%20Condensed%20Consolidated%20Statements%20of%20Operations) Q2 2025 net product revenue slightly increased to $15.01 million, gross margin improved, but higher SG&A led to a $3.80 million net loss | Income Statement Item (Thousands) | Q2 2025 (Thousands) | Q2 2024 (Thousands) | 6M 2025 (Thousands) | 6M 2024 (Thousands) | | :-------------------------------- | :---------- | :---------- | :---------- | :---------- | | Product revenue, net | $15,009 | $14,855 | $28,148 | $27,885 | | Cost of goods sold | $4,939 | $5,727 | $9,729 | $11,728 | | Research and development | $- | $913 | $39 | $8,797 | | Selling, general and administrative | $11,882 | $10,328 | $22,451 | $18,748 | | Total operating expenses | $17,885 | $17,782 | $34,348 | $40,902 | | Loss from operations | $(2,876) | $(2,927) | $(6,200) | $(13,017) | | Net loss | $(3,796) | $(3,361) | $(7,869) | $(13,803) | | Net loss per common share (Basic & Diluted) | $(0.16) | $(0.17) | $(0.34) | $(0.69) | Non-GAAP Financial Measures [Explanation of Non-GAAP Measures](index=6&type=section&id=Explanation%20of%20Non-GAAP%20Measures) Adjusted EBITDA is used for transparency, excluding non-cash or non-recurring items like share-based compensation, non-core R&D, and asset amortization - Adjusted EBITDA is defined as net income (loss) excluding interest, taxes, depreciation, and certain other non-cash and infrequent items not considered normal, recurring operating expenses[17](index=17&type=chunk) - Management uses non-GAAP measures to provide transparency, exclude non-cash/non-recurring items, and align with institutional investor analysis, but they should supplement, not substitute, GAAP measures[19](index=19&type=chunk) - Key exclusions from Adjusted EBITDA include share-based compensation, non-core and short-term R&D expenses (e.g., Emrosi pre-approval costs), and amortization/impairments of acquired intangible assets[20](index=20&type=chunk) [Reconciliation of GAAP to Non-GAAP Adjusted EBITDA](index=7&type=section&id=Reconciliation%20of%20GAAP%20to%20Non-GAAP%20Adjusted%20EBITDA) Q2 2025 GAAP Net Loss of $(3.80) million adjusted to a Non-GAAP Adjusted EBITDA of $(0.48) million, a decrease from Q2 2024, by adding back non-cash items | Reconciliation Item (Thousands) | Q2 2025 (Thousands) | Q2 2024 (Thousands) | 6M 2025 (Thousands) | 6M 2024 (Thousands) | | :------------------------------ | :---------- | :---------- | :---------- | :---------- | | GAAP Net Loss | $(3,796) | $(3,361) | $(7,869) | $(13,803) | | Interest | $799 | $402 | $1,541 | $733 | | Taxes | $60 | $- | $60 | $- | | Amortization of acquired intangible assets | $1,064 | $814 | $2,129 | $1,629 | | EBITDA | $(1,873) | $(2,145) | $(4,139) | $(11,441) | | Share-based compensation | $1,336 | $1,674 | $2,659 | $3,080 | | Short-term R&D | $- | $742 | $39 | $8,482 | | Non-GAAP Adjusted EBITDA | $(476) | $309 | $(1,373) | $321 | | Non-GAAP Adjusted EBITDA per share (Basic) | $(0.02) | $0.02 | $(0.06) | $0.02 | Corporate Information [About Journey Medical Corporation](index=2&type=section&id=About%20Journey%20Medical%20Corporation) Journey Medical Corporation is a commercial-stage pharmaceutical company marketing eight FDA-approved prescription dermatological products, founded by Fortress Biotech - Journey Medical Corporation is a commercial-stage pharmaceutical company focused on selling and marketing FDA-approved prescription dermatological products[1](index=1&type=chunk)[8](index=8&type=chunk) - The company currently markets **eight branded FDA-approved prescription drugs** for common skin conditions[8](index=8&type=chunk) - Journey Medical is located in Scottsdale, Arizona, and was founded by Fortress Biotech, Inc. (Nasdaq: FBIO)[8](index=8&type=chunk) [Forward-Looking Statements](index=3&type=section&id=Forward-Looking%20Statements) Forward-looking statements are subject to risks like regulatory challenges and Emrosi's commercialization, with no update obligation under the PSLRA - The press release includes forward-looking statements regarding growth strategy and product development, identified by words like 'anticipate,' 'believe,' 'expect,' and 'will'[11](index=11&type=chunk) - These statements are subject to risks and uncertainties, including regulatory hurdles, competition, market acceptance, reliance on third parties, and the successful commercialization of Emrosi[11](index=11&type=chunk) - The company disclaims any obligation to publicly update or revise forward-looking statements, claiming protection under the Private Securities Litigation Reform Act of 1995[11](index=11&type=chunk) [Conference Call and Webcast Information](index=2&type=section&id=Conference%20Call%20and%20Webcast%20Information) A conference call and webcast were held on August 12, 2025, at 4:30 p.m. ET to discuss financial results and provide a business update - A conference call and audio webcast were scheduled for August 12, 2025, at 4:30 p.m. ET[1](index=1&type=chunk)[5](index=5&type=chunk) - Participants could register online to receive dial-in numbers for the conference call[6](index=6&type=chunk) - A live audio webcast was accessible via the Investors section of Journey Medical's website and would be available for replay for approximately 30 days[7](index=7&type=chunk) [Company Contact Information](index=3&type=section&id=Company%20Contact%20Information) Contact details for investor relations (Jaclyn Jaffe) and media relations (Tony Plohoros) were provided for inquiries - Company Contact: Jaclyn Jaffe at (781) 652-4500 or ir@jmcderm.com[12](index=12&type=chunk) - Media Relations Contact: Tony Plohoros of 6 Degrees at (908) 591-2839 or tplohoros@6degreespr.com[12](index=12&type=chunk)

Core Insights - Journey Medical Corporation reported total revenues of $15.0 million for the second quarter of 2025, showing a slight increase from $14.9 million in the same quarter of the previous year [5] - Emrosi™ generated net sales of $2.8 million in its first full quarter on the market, indicating strong initial adoption and prescription ramp [2][5] - The company joined the Russell 2000® and Russell 3000® Indexes in June 2025, reflecting its growth and market presence [2][11] Financial Results - Total net product revenues for the second quarter of 2025 were $15.0 million, compared to $14.9 million in the prior year quarter [5] - Gross margin increased to 67% in Q2 2025 from 61% in Q2 2024, attributed to lower product costs and a favorable sales mix [5] - Selling, general and administrative expenses rose to $11.9 million in Q2 2025, up from $10.3 million in Q2 2024, primarily due to costs associated with the Emrosi launch [5] - The net loss for the second quarter was $3.8 million, or $(0.16) per share, compared to a net loss of $3.4 million, or $(0.17) per share, in the prior year [5][16] - At the end of Q2 2025, the company had $20.3 million in cash and cash equivalents, unchanged from December 31, 2024 [5] Recent Corporate Highlights - In July 2025, Journey Medical expanded payer access for Emrosi to over 100 million commercial lives in the U.S., up from 54 million in May 2025 [4] - The full commercial launch of Emrosi began on April 7, 2025, and has shown strong traction in the market [4] - Emrosi was featured in a segment on "The Balancing Act®" on Lifetime TV, highlighting treatment options for managing rosacea [11]